Trial Profile
PSMA PET Imaging of Recurrent Prostate Cancer
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 05 Jul 2023
Price :
$35
*
At a glance
- Drugs Gallium (68Ga) gozetotide (Primary)
- Indications Adenocarcinoma; Prostate cancer
- Focus Diagnostic use
- 29 Jun 2023 Planned End Date changed from 1 Jun 2023 to 1 Jun 2024.
- 29 Jun 2023 Planned primary completion date changed from 1 Jun 2023 to 1 Jun 2024.
- 06 Jul 2022 Planned number of patients changed from 1400 to 1171.